Precision targeting in hepatocellular carcinoma: Exploring ligand-receptor mediated nanotherapy

doi:10.4254/wjh.v16.i2.164

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1427)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

WORD

HTML

765

Figures (1-1)

Tables (1-3)

Sum=966

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

119

Download

160

Sum=279

Publishing Process of This Article

Item

Count

Browse

Download

114

Sum=165

Feb 27, 2024 (publication date) through May 14, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hepatol. Feb 27, 2024; 16(2): 164-176
Published online Feb 27, 2024. doi: 10.4254/wjh.v16.i2.164

Table 3 Summary of dual-targeted nanoformulations in hepatocellular carcinoma therapy

Ligand 1	Ligand 2	Nanocarrier	Payload	Particle size
Folic acid[100]	Lactobionic acid	Chitosan	5-Fu	163 ± 10 nm
Folic acid[101]	Lactobionic acid	Berberine; Diosmin	Casein micelles	Approximately 200 nm
Glycyrrhetinic acid[102]	Hyaluronic acid	Carbodiimide	Paclitaxe	200-320 nm
Lactobionic acid[103]	Glycyrrhetinic acid	Chitosan; Acrylic acid	DOX	Approximately 274 nm
Lactoferrin[104]	Lactobionic acid/Glycyrrhetinic acid	Phospholipid complex	Sorafenib; quercetin	169 ± 1.5; 230 ± 1.7
Biotin[105]	Lactobionic acid	PEG; PLGA	Curcumin 5-Fu	110-187 nm

5-Fu: 5-fluorouracil; DOX: Doxorubicin.

Citation: Zhou XQ, Li YP, Dang SS. Precision targeting in hepatocellular carcinoma: Exploring ligand-receptor mediated nanotherapy. World J Hepatol 2024; 16(2): 164-176
URL: https://www.wjgnet.com/1948-5182/full/v16/i2/164.htm
DOI: https://dx.doi.org/10.4254/wjh.v16.i2.164